Tevogen Bio Holdings INC

Tevogen Bio Holdings Inc. has officially changed its corporate name to Tevogen Inc., effective July 30, 2026, with no impact on security holders or trading symbols.

Tevogen Bio Holdings Inc. has been notified by Nasdaq that it fails to meet minimum market value requirements for continued listing.

Tevogen Bio Holdings Inc. announced it has regained compliance with Nasdaq's minimum bid price requirement following a 1-for-50 reverse stock split.

Tevogen Bio Holdings Inc. announced a 1-for-50 reverse stock split to regain compliance with Nasdaq's minimum bid price requirement, effective March 6, 2026.

Tevogen Bio Holdings Inc. stockholders approved a significant increase in shares for its incentive plan and authorized a reverse stock split to be implemented at the Board's discretion.

Tevogen Bio Holdings Inc. announced its Board of Directors intends to evaluate a potential one-time special cash dividend to shareholders, contingent on future financial milestones.

Tevogen Bio Holdings Inc. reported a net loss of $5.7 million for Q3 2025, while securing additional financing and facing a Nasdaq minimum bid price non-compliance notice.

Tevogen Bio Holdings Inc. reported continued net losses and negative cash flows for Q2 2025, pausing clinical trials until further funding is secured despite recent capital raises and commitments.

Tevogen Bio Holdings Inc. reports a net loss of $10.4 million for the first quarter of 2025, primarily due to operating expenses and non-cash stock-based compensation.

Tevogen Bio Holdings Inc. reported its financial results for the third quarter ended September 30, 2024, highlighting ongoing research and development efforts in T-cell therapy.

Tevogen Bio Holdings Inc. reported a net loss for the second quarter of 2024, alongside significant developments in financing and operational activities.

Tevogen Bio Holdings reported a net income of $11.3 million for Q1 2024, primarily due to a change in the fair value of convertible promissory notes, but faces substantial doubt about its ability to continue as a going concern.

Tevogen Bio Holdings Inc. filed an amendment to its 2025 Annual Report to include required Part III information previously omitted from the original filing.

Tevogen Bio Holdings Inc. reported a net loss of $26.3 million for 2025, alongside positive Phase 1 clinical trial results for TVGN 489 and ongoing development of its ExacTcell technology.

Tevogen Bio Holdings Inc. details its financial standing, development strategy, and regulatory landscape in its annual 10-K filing, emphasizing its ExacTcell technology and lead product candidate, TVGN 489.

Tevogen Bio Holdings Inc. outlines the terms of its common and preferred stock, warrants, and various corporate governance provisions in its latest 10-K filing.

Victor J. Sordillo, a Director at Tevogen Bio Holdings Inc., was granted 40,000 shares of common stock under the company's 2024 Omnibus Incentive Plan.

Tevogen Bio Holdings Inc. reports a significant stock grant to CEO Ryan H. Saadi, comprising 1.22 million restricted shares vesting over four years.

Tevogen Bio Holdings Inc. reports a stock grant to Director Susan M. Podlogar, with vesting tied to significant revenue milestones.

Tevogen Bio Holdings Inc. reports a restricted stock grant to Director Curtis L. Patton, with vesting tied to revenue milestones.

Tevogen Bio Holdings Inc. reports a restricted stock grant to Director Goh Keow Lin, with vesting tied to revenue milestones and continued service.

Tevogen Bio Holdings Inc. reports a restricted stock grant to Director Feike Jeffrey L., with vesting tied to significant revenue milestones.

Tevogen Inc. has announced its 2026 Annual Meeting of Stockholders, scheduled for August 24, 2026, to elect directors, ratify auditors, and approve amendments to its incentive plan and charter.

Tevogen Bio Holdings Inc. calls a special meeting to vote on a reverse stock split to maintain Nasdaq listing and a significant increase in its equity incentive plan shares.

Tevogen Bio Holdings Inc. has filed a definitive proxy statement with the SEC.

Tevogen Bio Holdings Inc. will hold its 2025 Annual Meeting of Stockholders virtually on June 23, 2025, to elect directors and ratify the appointment of KPMG LLP as the company's independent registered public accounting firm.

Tevogen Bio will hold its 2025 annual meeting of stockholders via live webcast on June 23, 2025, to vote on director re-election and ratification of the company's accounting firm.

Tevogen Bio Holdings seeks to register the resale of common stock and warrants, potentially raising $207 million through warrant exercises for general corporate purposes.

Tevogen Bio Holdings Inc. is amending its S-1 registration statement to include details on the issuance and resale of common stock and warrants, aiming to raise capital for general corporate purposes.

Tevogen Bio Holdings seeks to register the resale of a substantial number of common shares and warrants, potentially impacting its stock price.

Ryan Saadi, CEO of Tevogen Bio Holdings Inc., reports increased beneficial ownership following a restricted stock grant.

Ryan H. Saadi, founder of Tevogen Bio Holdings Inc., updated his beneficial ownership to 62% after gifting 460,000 shares to charitable entities.

Tevogen Bio Holdings Inc. CEO Ryan Saadi increased his beneficial ownership to 64.5% with a new 8 million share restricted stock grant, while also disclosing a recent sale of over 1.4 million shares.